WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
P.O.Box 4404 Nydalen
0403 Oslo
Norway

Visiting/delivery address:
Marcus Thranes gate 6
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

Alterations in ATCvet codes

 Alterations included in the ATCvet Index valid from 2017

Previous ATCvet codeATCvet level name New ATCvet code
QA10BX04exenatideQA10BJ01
QA10BX07liraglutideQA10BJ02
QA10BX09dapagliflozinQA10BK01
QA10BX10lixisenatideQA10BJ03
QA10BX11canagliflozinQA10BK02
QA10BX12empagliflozinQA10BK03
QA10BX13albiglutideQA10BJ04
QA10BX14dulaglutideQA10BJ05
QB02BD09nonacog alfaQB02BD04 1)
QB02BD12trenonacog alfaQB02BD04 1)
QG04BC90tiotropinQG04BX16 2)
QL01BA01methotrexateQL04AX03 3)
QL04AC06mepolizumabQR03DX09
QR05CB12tioproninQG04BX16 2)
1) Existing ATCvet code QB02BD04 coagulation factor IX
2) ATCvet code QG04BC90 and QR05CB12 are merged together in one ATCvet code QG04BX16 due to changes in the human ATC system.
3) Splitting of ATCvet code. Only the classification of pre-filled syringe/pen of methotrexate for use in non-cancer indications is changed. These products will be moved to the existing ATCvet code for oral administered product of methotrexate. Parenteral preparations used for treatment of cancer will remain in QL01BA01.

Other alterations in ATCvet 2017

Alterations included in the ATCvet Index valid from 2017

ATCvet codePrevious ATCvet level name New ATCvet level name or new ATCvet level
QA10BJGlucagon-like peptide-1 (GLP-1) analogues
QA10BKSodium-glucose co-transporter 2 (SGLT2) inhibitors
QC07FXBeta blocking agents, other combinations
QN02AJ 1)Opioids in combination with non-opioid analgesics
QC07AA57sotalol, combinationsQC07FX02sotalol and acetylsalicylic acid
QC07AB52metoprolol, combinationsQC07FX03metoprolol and acetylsalicylic acid
QC07AB57bisoprolol, combinationsQC07FX04bisoprolol and acetylsalicylic acid
QC07FBeta blocking agents and other antihypertensivesQC07FBeta blocking agents, other combinations
QC07FABeta blocking agents, non-selective, and other antihypertensivesDeleted
QC07FA05propranolol and other antihypertensivesC07FX01propranolol and other combinations
QC07FBBeta blocking agents, selective, and other antihypertensivesQC07FBBeta blocking agents and calcium channel blockers
QC07FB02 2)metoprolol and other antihypertensivesQC07FB02
QC07FB13
metoprolol and felodipine 3)
metoprolol and amlodipine
QC07FB03atenolol and other antihypertensivesQC07FB03atenolol and nifedipine
QC07FB07bisoprolol and other antihypertensivesQC07FB07bisoprolol and amlodipine
QC07FB12nebivolol and other antihypertensivesQC07FB12nebivolo and amlodipine
QM01AE51 1)Ibuprofen, combinationsQN02AJ03

QN02AJ08
dihydrocodeine and other non-opioid analgesics
codeine and ibuprofen
QN02AA55 1)oxycodone, combinationsQN02AA55
QN02AJ17
QN02AJ18
QN02AJ19
oxycodone and naloxone
oxycodone and paracetamol
oxycodone and acetylsalicylic acid
oxycodone and ibuprofen
QN02AA58 1)dihydrocodeine, combinationsQN02AJ01
QN02AJ02

QN02AJ03
dihydrocodeine and paracetamol
dihydrocodeine and acetylsalicylic acid
dihydrocodeine and other non-opioid analgesics
QN02AA59 1)codeine, combinations excl. psycholepticsQN02AJ06
QN02AJ07
QN02AJ08
QN02AJ09
codeine and paracetamol
codeine and acetylsalicylic acid
codeine and ibuprofen
codeine and other non-opioid analgesics
QN02AX52tramadol, combinationsQN02AJ13
QN02AJ14
QN02AJ15
tramadol and paracetamol
tramadol and dexketoprofen
tramadol and other non-opioid analgesics
QN02BA51 1)acetylsalicylic acid, combinations excl. psycholepticsQN02AJ02

N02AJ07
QN02AJ18
dihydrocodeine and acetylsalicylic acid
codeine and acetylsalicylic acid
oxycodone and acetylsalicylic acid
QN02BE51 1)paracetamol, combinations excl. psycholepticsQN02AJ01
QN02AJ06
QN02AJ09

QN02AJ17
dihydrocodeine and paracetamol
codeine and paracetamol
codeine and other non-opioid analgesics
oxycodone and paracetamol
1) Splitting of ATCvet codes according to contents of the different fixed combinations of opioids and other analgesics. The ATCvet codes in QN02A, QN02BA51, QN02BE51 and QM01AE51 will be maintained for other combinations. Combinations with opioids and non-opioid analgesics currently classified in the following ATCvet codes QN02AA55, QN02AA58, QN02AA59 will be moved to the new ATCvet 4th level QN02AJ. All the existing combination codes will be kept in QN02A since there may be other combinations without analgesics available (e.g. oxycodone and naloxone will remain in QN02AA55). The ATCvet classification of all low dose (<20 mg dose) combinations products of codeine or dihydrocodeine currently classified in QN02B or QM01A will be altered to the new ATCvet codes in QN02AJ.
2) Splitting of ATCvet code in connection with alterations in QC07FX.
3) Unchanged ATCvet code, ATCvet level name changed.

Last updated: 2017-01-26